New Jersey Administrative Code
Title 13 - LAW AND PUBLIC SAFETY
Chapter 39 - STATE BOARD OF PHARMACY
Subchapter 13 - COLLABORATIVE PRACTICE
Section 13:39-13.6 - Informed consent for collaborative drug therapy management
Universal Citation: NJ Admin Code 13:39-13.6
Current through Register Vol. 56, No. 6, March 18, 2024
(a) Written informed consent shall be obtained from each individual patient participating in collaborative drug therapy management. Both the physician and the pharmacist shall retain a copy of the patient's written informed consent. The written informed consent shall:
1. Contain the specific patient's name;
2. Identify the risks and benefits of collaborative drug therapy management, including the fact that services provided under collaborative drug therapy management may not be covered by the patient's insurance provider;
3. Identify the fact that covering physicians and/or pharmacists may be utilized in the collaborative drug therapy management of the patient's care;
4. Identify the patient's right to elect to participate in and withdraw from the collaborative drug therapy management; and
5. Be signed and dated by the patient.
Disclaimer: These regulations may not be the most recent version. New Jersey may have more current or accurate information. We make no warranties or guarantees about the accuracy, completeness, or adequacy of the information contained on this site or the information linked to on the state site. Please check official sources.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.
